Bayer (BAYN) Given a €90.00 Price Target by Sanford C. Bernstein Analysts

Sanford C. Bernstein set a €90.00 ($104.65) price target on Bayer (FRA:BAYN) in a report released on Thursday, Borsen Zeitung reports. The brokerage currently has a buy rating on the healthcare company’s stock.

A number of other brokerages also recently issued reports on BAYN. Deutsche Bank set a €115.00 ($133.72) price objective on Bayer and gave the company a buy rating in a research note on Friday, March 1st. Barclays set a €85.00 ($98.84) price objective on Bayer and gave the company a buy rating in a research note on Monday, March 4th. JPMorgan Chase & Co. set a €70.00 ($81.40) price objective on Bayer and gave the company a neutral rating in a research note on Friday, March 1st. Kepler Capital Markets set a €84.00 ($97.67) price objective on Bayer and gave the company a buy rating in a research note on Wednesday, February 27th. Finally, Nord/LB set a €72.00 ($83.72) price target on Bayer and gave the stock a neutral rating in a research note on Wednesday, February 27th. One research analyst has rated the stock with a sell rating, eleven have assigned a hold rating and twelve have given a buy rating to the company’s stock. Bayer currently has a consensus rating of Hold and an average target price of €81.80 ($95.12).

Shares of FRA:BAYN opened at €61.16 ($71.12) on Thursday. Bayer has a 1 year low of €91.58 ($106.49) and a 1 year high of €123.82 ($143.98).

Bayer Company Profile

Bayer Aktiengesellschaft operates as a life science company worldwide. It operates through Pharmaceuticals, Consumer Health, Crop Science, and Animal Health segments. The Pharmaceuticals segment offers prescription products primarily for cardiology and women's health care; specialty therapeutics in the areas of oncology, hematology, and ophthalmology; and diagnostic imaging equipment and contrast agents.

Further Reading: The Role of a Fiduciary and Individual Investors

Analyst Recommendations for Bayer (FRA:BAYN)

Receive News & Ratings for Bayer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bayer and related companies with MarketBeat.com's FREE daily email newsletter.